Correction – Admission Date for New Ordinary Shares Included
This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No 596/2014.
Cambridge, UK and Indianapolis, US – 16 December 2021: Acacia Pharma Group plc (“Acacia Pharma”, the “Group” or the “Company”) (EURONEXT: ACPH), a hospital pharmaceutical company focused on the development and commercialization of new products aimed at improving the care of patients undergoing significant treatments such as surgery, other invasive procedures or cancer chemotherapy, was notified on 14 December 2021 that the Company's Employee Benefit Trust ("EBT") intends to subscribe for 1,145,472 new ordinary shares in the Company at their par value of 2p each and at an aggregate cost to the EBT of £22,909.44. ("New Ordinary Shares"). The Company has agreed to lend £22,909.44 to the EBT to fund its subscription for the New Ordinary Shares. The New Ordinary Shares to be held in the EBT are intended to be used to satisfy previously announced awards arising from the Company's employee incentive schemes.
Accordingly, on 16 December 2021, the Company allotted the New Ordinary Shares to the EBT and such shares will rank pari passu in all respects with the existing ordinary shares of the Company. The New Ordinary Shares were admitted to trading on Euronext on 16 December 2021 ("Admission").
Following the issue of the New Ordinary Shares, the Company's total issued share capital consists of 100,859,423 ordinary shares with one voting right per share. The Company does not hold any ordinary shares in treasury. Therefore, following the issue of the New Ordinary Shares, the total number of voting rights in the Company is 100,859,423.